⌕
Inhibrx Biosciences · INBX · Nasdaq
Tenet 45 · Mixed
Compare
$74.18−4.48%At closeTenet 45 · Mixed
$74.18−3.48 (−4.48%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Inhibrx Biosciences (INBX) Income Statement

Is this a real, growing, cash-generative business, or a story propped up by accounting?

Sources Company filings FilingsHow we compute thisNot investment advice

10 figures withheld by our checks. Each blank figure names its reason.

Business engineChoppy: revenue compounds ~−15.0%/yr (FY23→FY25), net margin −10773.5%.
The four lines that matter · FY23–FY25
Revenue ($M)▲550.0%
1.3
FY23→FY25CAGR −15.0%/yr
Net income ($M)—
−140.1
FY23→FY25CAGR —
Free cash flow ($M)▲34.1%
−129.8
FY23→FY25CAGR —
Diluted EPS—
−9.04
FY23→FY25CAGR —
What the income statement says · FY23–FY25
Where every revenue dollar goes · FY25 ($M)1.3Revenue0.0COGS−113.0R&D−23.3SG&A−135.0Op income−5.0Tax & other−140.1Net income

-10773¢ of every revenue dollar becomes profit.

Margin trend · direction beats level Operating Net
8437906328434218952109480%sector median net margin ~3%FY23FY25

Net margin -10773.5% is below the sector median. This filer reports no gross profit line, so that margin is not drawn.

The receipt · income statement · FY23–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
Line itemTTM †FY25FY24FY23YoYCAGR 23→25
Revenue & profitability
Revenue
2,000.01,300.0200.01,800.0▲550.0%−15.0%
Cost of revenue
—0.00.00.0——
Gross profit
—A—A—A—A——
Research & development
100,431.0113,028.0203,743.0191,640.0▼44.5%−23.2%
Selling, general & admin
27,303.023,297.0127,905.029,381.0▼81.8%−11.0%
Total operating expenses
127,734.0136,325.0331,648.0221,021.0▼58.9%−21.5%
Operating incomefeeds ROC rank
−125,734.0−135,025.0−331,448.0−219,221.0▲59.3%—
Other income, net
−15,921.0−5,028.02,019,022.0−20,503.0——
Pretax income
−141,655.0−140,053.01,687,574.0−239,724.0——
Income tax
3.02.02.03.0▲0.0%−18.4%
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings
−141,658.0−140,055.01,687,572.0−241,361.0——
Per share
Diluted EPSbuyback-sensitive
−9.06−9.04112.62−20.48——
Diluted shares (mn)
15.7215.4914.9811.78▲3.4%+14.6%
Margins
Gross margin
—A—A—A—A——
Operating margin
−6286.7%−10386.5%−165724.0%−12178.9%▲155337.5pp+1792.4pp
Net margin
−7082.9%−10773.5%843786.0%−13408.9%▼854559.5pp+2635.5pp
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
CSV export is on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
Annual report filed 2026-03-19 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.

What was Inhibrx Biosciences' revenue last fiscal year?

Inhibrx Biosciences reported revenue of $1.3M in fiscal 2025, up 550.0% from fiscal 2024.

What was Inhibrx Biosciences' net income?

Inhibrx Biosciences reported net income of −$140.1M in fiscal 2025, a net margin of −10773.5%.

Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.